An evaluation of the role of 5-HT2 receptor antagonism during subchronic antipsychotic drug administration in rats

Brain Research

Volumn 875, Issue 1-2, 2000, Pages 35-43

  Kruzich, Paul J ^a   See, Ronald E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antipsychotic; Clozapine; Dopamine; Haloperidol; Risperidone; Striatum

Indexed keywords

CLOZAPINE; DOPAMINE; HALOPERIDOL; RACLOPRIDE; RISPERIDONE; RITANSERIN; SEROTONIN 2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE UPTAKE; DRUG RECEPTOR BINDING; FEMALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CATALEPSY; CORPUS STRIATUM; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; FEMALE; MICRODIALYSIS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN ANTAGONISTS; TIME FACTORS;

EID: 0034284951     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)02574-9     Document Type: Article

References (48)

1. Andersson J.L., Nomikos G.G., Marcus M., Hertel P., Mathe J.M., Svensson T.H. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. Naunyn Schmiedebergs Arch. Pharmacol. 352:1995;374-385.
2. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 18:1998;63-101.
3. Balsara J.J., Jadhav J.H., Chandorkar A.G. Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology (Berl.). 62:1979;67-69.
4. Barnes D.E., Robinson B., Csernansky J.G., Bellows E.P. Sensitization versus tolerance to haloperidol-induced catalepsy: multiple determinants. Pharmacol. Biochem. Behav. 36:1990;883-887.
5. Booth R.G., Baldessarini R.J., Campbell A. Inhibition of dopamine synthesis in rat striatal minces: evidence of dopamine autoreceptor supersensitivity to S(+)- but not R(-)-N-n-propylnorapomorphine after pretreatment with fluphenazine. Biochem. Pharmacol. 41:1991;2040-2043.
6. Broekkamp C.L., Oosterloo S.K., Berendsen H.H., van Delft A.M. Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. Naunyn Schmiedebergs Arch. Pharmacol. 338:1988;191-195.
7. Brown C.S., Markowitz J.S., Moore T.R., Parker N.G. Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs. Ann. Pharmacother. 33:1999;210-217.
8. Campbell A., Baldessarini R.J. Tolerance to behavioral effects of haloperidol. Life Sci. 29:1981;1341-1346.
9. Coward D.M., Imperato A., Urwyler S., White T.G. Biochemical and behavioural properties of clozapine. Psychopharmacology (Berl.). 99:1989;S6-12.
10. Dewey S.L., Smith G.S., Logan J., Alexoff D., Ding Y.S., King P., Pappas N., Brodie J.D., Ashby C.R. Jr. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J. Neurosci. 15:1995;821-829.
11. Drago F., Contarino A., Marino R., Anzallo C., Valerio C., Rampello L., Raffaele R., Scapagnini U. Effects of acute or chronic administration of risperidone on motor and sexual behavior of male rats. Pharmacol. Res. 35:1997;17-25.
12. Ellenbroek B., Cools A.R. The paw test: an animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism. Life Sci. 42:1988;1205-1213.
13. Ellenbroek B.A., Prinssen E.P., Cools A.R. The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats. Eur. J. Neurosci. 6:1994;1-8.
14. Ezrin-Waters C., Seeman P. Tolerance of haloperidol catalepsy. Eur. J. Pharmacol. 41:1977;321-327.
15. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 49:1992;538-544.
16. Grimm J.W., See R.E. Unique activation of extracellular striato-pallidal neurotransmitters in rats following acute risperidone. Brain Res. 801:1998;182-189.
17. Hertel P., Fagerquist M.V., Svensson T.H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science. 286:1999;105-107.
18. Hertel P., Nomikos G.G., Iurlo M., Svensson T.H. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berl.). 124:1996;74-86.
19. Hicks P.B. The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci. 47:1990;1609-1615.
20. Ichikawa J., Meltzer H.Y. Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens. J. Pharmacol. Exp. Ther. 256:1991;348-357.
21. Janicak P.G., Davis J.M., Preskorn S.H., Ayd F.J. Principles and Practice of Psychopharmacotherapy. 1997;Williams and Wilkins, Baltimore, MD.
22. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry. 153:1996;466-476.
23. Leysen J.E., Gommeren W., Van Gompel P., Wynants J., Janssen P.F., Laduron P.M. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol. Pharmacol. 27:1985;600-611.
24. Leysen J.E., Janssen P.M., Megens A.A., Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry. 55:(Suppl.):1994;5-12.
25. Lucas G., Bonhomme N., De Deurwaerdere P., Le Moal M., Spampinato U. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology (Berl.). 131:1997;57-63.
26. Lucas G., Spampinato U. Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem. 74:2000;693-701.
27. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry. 151:1994;825-835.
28. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl.). 99:1989;S18-27.
29. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci. 3:1995;64-75.
30. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54:1990;1755-1760.
31. Neal-Beliveau B.S., Joyce J.N., Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J. Pharmacol. Exp. Ther. 265:1993;207-217.
32. Niemegeers C.J., Janssen P.A. A systematic study of the pharmacological activities of dopamine antagonists. Life Sci. 24:1979;2201-2216.
33. O’Connor W.T., Drew K.L., Ungerstedt U. Differences in dopamine release and metabolism in rat striatal subregions following acute clozapine using in vivo microdialysis. Neurosci. Lett. 98:1989;211-216.
34. Ogren S.O. The behavioural pharmacology of typical and atypical antipsychotic drugs. Csernansky J.G. Antipsychotics. Handbook of Experimental Pharmacology. 120:1996;225-266 Springer, Berlin.
35. Paxinos G., Watson D. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, New York.
36. Prinssen E.P., Ellenbroek B.A., Cools A.R. Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur. J. Pharmacol. 262:1994;167-170.
37. Puri S.K., Lal H. Tolerance to the behavioral and neurochemical effects of haloperidol and morphine in rats chronically treated with morphine or haloperidol. Naunyn Schmiedebergs Arch. Pharmacol. 282:1974;155-170.
38. Rao S.G., Hrishikeshavan H.J., Guruswami M.N. Effect of serotonergic agents on neuroleptic induced catalepsy in rats. Funct. Neurol. 5:1990;353-360.
39. Robinson T.E., Whishaw I.Q. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res. 450:1988;209-224.
40. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.). 124:1996;57-73.
41. See R.E., Kalivas P.W. Tolerance and sensitization to the effects of antipsychotic drugs on dopamine transmission. Csernansky J.G. Antipsychotics. Handbook of Experimental Pharmacology. 120:1996;203-224 Springer, Berlin.
42. See R.E., Chapman M.A. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats. Eur. J. Pharmacol. 263:1994;269-276.
43. See R.E., Chapman M.A. The consequences of long-term antipsychotic drug administration on basal ganglia neuronal function in laboratory animals. Crit. Rev. Neurobiol. 8:1994;85-124.
44. See R.E., Murray C.E. Changes in striatal dopamine release and metabolism during and after subchronic haloperidol administration in rats. Neurosci. Lett. 142:1992;100-104.
45. Seeman P., Tallerico T., Corbett R., Van Tol H.H., Kamboj R.K. Role of dopamine D2, D4 and serotonin(2A) receptors in antipsychotic and anticataleptic action. J. Psychopharmacol. 11:1997;15-17.
46. Yamamoto B.K., Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14:1994;4159-4166.
47. Zetterstrom T., Sharp T., Ungerstedt U. Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. Eur. J. Pharmacol. 106:1984;27-37.
48. Zhang W., Tilson H., Stachowiak M.K., Hong J.S. Repeated haloperidol administration changes basal release of striatal dopamine and subsequent response to haloperidol challenge. Brain Res. 484:1989;389-392.